8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ofthe Securities Exchange Act of 1934

Dateof Report (Date of earliest event reported): March5, 2026

PROFOUND MEDICAL CORP.

(Exact name of Registrant as Specified in ItsCharter)

Registrant’s Telephone Number, Including Area Code: 647-476-1350

(Former Name or Former Address, if Changed SinceLast Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) ofthe Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or CertainOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 5, 2026, Kris Shah notified the Board of Directors (the “Board”) of Profound Medical Corp. (the “Company”) of his resignation from the Board, effective immediately. This resignation was not the result of any disagreement with the Company.

Effective immediately upon such resignation, the Board appointed Frank Baylis to serve as a director to fill the vacancy created by Mr. Shah’s resignation. Mr. Baylis will serve until the Company’s 2026 annual meeting of stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

There are no arrangements or understandings between Mr. Baylis and any other person pursuant to which he was appointed as a director, and there are no family relationships between Mr. Baylis and any director or executive officer of the Company. There are no transactions to which the Company is a party and in which Mr. Baylis has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K.

Mr. Baylis will be entitled to the compensation paid by the Company to its non-employee directors, including an annual retainer of $50,000 for service on the Board (pro-rated for the portion of the year in which he serves as a member of the Board) and will be eligible to receive an annual equity award.

Mr. Baylis also entered into the Company’s standard form of indemnification agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.